or Try an Advanced Search...

    Technical Analysis for DAWN - Day One Biopharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 13.58 -1.45% -0.20
    DAWN closed down 1.45 percent on Monday, July 1, 2024, on 58 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical DAWN trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    Weak + Overbought Other 0.00%
    Overbought Stochastic Strength 0.00%
    200 DMA Resistance Bearish -1.45%
    NR7 Range Contraction -1.45%
    Stochastic Reached Overbought Strength -1.45%
    Weak + Overbought Other -1.45%
    Weak, Overbought and Reversal Signs Reversal -1.45%
    Overbought Stochastic Strength -1.45%
    Upper Bollinger Band Touch Strength -1.45%
    Older End-of-Day Signals for DAWN ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 8 hours ago
    200 DMA Resistance about 8 hours ago
    Down 3% about 8 hours ago
    Fell Below Previous Day's Low about 8 hours ago
    Down 2 % about 8 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    DAWN Chart by TradingView
    Basic chart:

    Profile

    Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Enzymes Protein Kinase Inhibitor Signal Transduction Protein Kinase Kinase Ym Biosciences

    Is DAWN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 Lupita Nyong’o Shimmers in Sequined Off-the-shoulder Prada Jumpsuit and Satin Miniskirt at ‘A Quiet Place: Day One’ Premiere
    Jun 24 Lupita Nyong’o Gives Power Suiting a Sensual Spin in Double-breasted Blazer and High-waisted Shorts for ‘A Quiet Place: Day One’ Photo Call
    Jun 22 Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)
    Jun 19 Day One targets the growing ADC market with MabCare acquisition
    Jun 18 Day One in licensing pact with MabCare for cancer therapy
    Jun 18 Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
    Jun 11 Exclusive: Day One Ventures closes its third fund at $150 million
    May 30 Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
    May 30 Day One Announces Sale of Priority Review Voucher for $108 Million
    May 6 Day One Biopharmaceuticals GAAP EPS of -$0.72 misses by $0.06
    See more DAWN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.0699
    52 Week Low 9.67
    Average Volume 1,276,895
    200-Day Moving Average 13.85
    50-Day Moving Average 14.59
    20-Day Moving Average 13.10
    10-Day Moving Average 13.38
    Average True Range 0.73
    RSI (14) 49.24
    ADX 16.98
    +DI 19.06
    -DI 20.35
    Chandelier Exit (Long, 3 ATRs) 11.91
    Chandelier Exit (Short, 3 ATRs) 14.12
    Upper Bollinger Bands 14.04
    Lower Bollinger Band 12.16
    Percent B (%b) 0.76
    BandWidth 14.36
    MACD Line -0.19
    MACD Signal Line -0.38
    MACD Histogram 0.1885
    Fundamentals Value
    Market Cap 1.18 Billion
    Num Shares 87 Million
    EPS -2.29
    Price-to-Earnings (P/E) Ratio -5.93
    Price-to-Sales 0.00
    Price-to-Book 3.40
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 14.39
    Resistance 3 (R3) 14.39 14.13 14.26
    Resistance 2 (R2) 14.13 13.92 14.13 14.21
    Resistance 1 (R1) 13.85 13.79 13.72 13.85 14.16
    Pivot Point 13.59 13.59 13.52 13.59 13.59
    Support 1 (S1) 13.31 13.38 13.18 13.31 13.00
    Support 2 (S2) 13.05 13.25 13.05 12.95
    Support 3 (S3) 12.77 13.05 12.91
    Support 4 (S4) 12.77